/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

EyePoint Inc Share Price Today: Live Updates & Key Insights

EyePoint Inc share price today is $14.18, up -5.97%. The stock opened at $14.62 against the previous close of $14.92, with an intraday high of $14.6545 and low of $13.52.

EyePoint Inc Share Price Chart

style
pb-0

EyePoint Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

EyePoint Inc Share Price Performance

$14.18 -0.0597(-5.97%) EYPT at 13 Mar 2026 12:57 PM Biotechnology
Lowest Today 13.52
Highest Today 14.6545
Today’s Open 14.62
Prev. Close 14.92
52 Week High 19.11
52 Week Low 3.91
Day’s Range: Low 13.52 High 14.6545
52-Week Range: Low 3.91 High 19.11
1 day return -
1 Week return -11.13
1 month return +8.58
3 month return -14.44
6 month return +4.89
1 year return +105.56
3 year return +446.3
5 year return +19.79
10 year return -

EyePoint Inc Institutional Holdings

Cormorant Asset Management, LLC 9.98

Suvretta Capital Management, LLC 9.38

BlackRock Inc 5.95

Vanguard Group Inc 5.78

Adage Capital Partners Gp LLC 5.63

Federated Hermes Inc 5.29

Franklin Resources Inc 5.00

Paradigm Biocapital Advisors LP 4.42

TCG Crossover Management, LLC 4.28

Federated Hermes Kaufmann Growth 3.32

Federated Hermes Kaufmann R 3.32

Vanguard Total Stock Mkt Idx Inv 3.12

Franklin Biotechnology Discv A(acc)USD 2.63

Citadel Advisors Llc 2.56

Federated Hermes Kaufmann Small Cap A 2.38

Federated Hermes Kaufmann Small Cap Grow 2.38

iShares Russell 2000 ETF 2.20

Orbimed Advisors, LLC 2.15

Aberdeen Group PLC 1.92

Geode Capital Management, LLC 1.83

The Goldman Sachs Group Inc 1.82

State Street Corp 1.77

Franklin Small Cap Growth Adv 1.54

Franklin US Small Cap Growth Equity 1.54

Franklin Biotechnology Discovery A 1.52

Parkman Healthcare Partners LLC 1.30

Essex Woodlands Health Ventures 1.30

abrdn Healthcare Investors 1.28

5AM Venture Management, LLC 1.26

Bank of America Corp 1.21

Morgan Stanley - Brokerage Accounts 1.17

Biotech Growth Ord 1.06

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Fidelity Small Cap Index 0.89

HSBC GIF Glb Eq Sust Hlthcare AC USD 0.84

Candriam Eqs L Biotech C USD Cap 0.81

iShares Russell 2000 Value ETF 0.78

abrdn Life Sciences Investors 0.64

Federated Hermes MDT SCC Institutional 0.55

Federated Hermes MDT Small Cap Core IS 0.55

EyePoint Inc Market Status

Strong Buy: 9

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

EyePoint Inc Fundamentals

Market Cap 1244.80 M

PB Ratio 3.7825

PE Ratio 0.0

Enterprise Value 959.49 M

Total Assets 364.00 M

Volume 1802424

EyePoint Inc Company Financials

Annual Revenue FY23:42523000 42.5M, FY22:41404000 41.4M, FY21:36939000 36.9M, FY20:34437000 34.4M, FY19:20365000 20.4M

Annual Profit FY23:35479000 35.5M, FY22:33078000 33.1M, FY21:28762000 28.8M, FY20:28613000 28.6M, FY19:17678000 17.7M

Annual Net worth FY23:-100148000 -100.1M, FY22:-124512000 -124.5M, FY21:-63915000 -63.9M, FY20:-52651000 -52.7M, FY19:-62969000 -63.0M

Quarterly Revenue Q3/2025:966000 1.0M, Q2/2025:5333000 5.3M, Q1/2025:24453000 24.5M, Q3/2024:10524000 10.5M, Q2/2024:9477000 9.5M

Quarterly Profit Q3/2025:245000 0.2M, Q2/2025:5168000 5.2M, Q1/2025:23648000 23.6M, Q3/2024:9788000 9.8M, Q2/2024:8076000 8.1M

Quarterly Net worth Q3/2025:-59732000 -59.7M, Q2/2025:-59426000 -59.4M, Q1/2025:-45195000 -45.2M, Q3/2024:-29361000 -29.4M, Q2/2024:-30826000 -30.8M

About EyePoint Inc & investment objective

Company Information EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 214

Industry Biotechnology

CEO Dr. Jay S. Duker M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow